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Gentamicin and phenytoin sieving through hollow—fiber polysuffone
hemofilters. The sieving characteristics of the prototype drugs gentami-
cm (poorly protein bound) and phenytoin (highly protein bound) were
measured in vitro using polysulfone capillary hemofilters similar to
those used in clinical continuous arteriovenous hemofiltration. Plasma
water, whole plasma, and whole blood were the solvent systems used
with variable drug concentrations and solvent flow rates. Our results
indicate that the sieving coefficients for both drugs can be accurately
defined as the concentration in the ultrafiltrate divided by the concen-
tration in the artery. This correlates with a more rigorously derived
expression by Colton and Henderson (r 0.98, P < 0.00001 for both
drugs) and avoids the necessity of measuring venous concentrations.
Drug sieving in the three solvents followed expectations from known
protein—binding data and was independent of solvent flow rate. For both
drugs, at higher drug concentrations sieving increased in plasma,
consistent with the saturation of protein—binding sites. In whole blood,
sieving fell for both drugs with increasing drug concentrations, consist-
ent with drug compartmentalization into red blood cells. Although these
sieving changes with increasing drug concentrations were statistically
significant, their clinical significance is doubtful. Phenytoin sieving in
plasma was increased by the addition of free fatty acids, consistent with
a protein—drug displacement effect. There appears to be a real, but
small, effect of protein concentration polarization, protein—membrane
and drug—membrane interactions on drug sieving. Our observations are
consistent with the expectation that the major determinant of drug
sieving is the extent of drug—protein binding.
Drug handling during continuous arteriovenous hemofil-
tration (CAVH) is mentioned only briefly in descriptions of this
new technology [1—3]. An initial report [4] and subsequent
review [5] from our unit have emphasized the potential clinical
importance of this aspect of patient management. Drugs are
solutes but often during hemofiltration they do not behave like
test solutes (such as, endogenous urea and creatinine, and
exogenous inulin and dextran) because of their binding to
circulating plasma proteins. Protein—bound solutes will not be
ultrafilterable. Other factors known to affect solute sieving
include blood flow and ultrafiltration rate (UFR) [6—10].
The current studies were designed to investigate the sieving
characteristics of two prototype drugs in an in vitro model of
continuous arteriovenous hemofiltration where blood flow and
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ultrafiltration rates are considerably less than those observed
during intermittent high flux hemofiltration. Gentamicin and
phenytoin were selected as study drugs because of their low and
high protein binding, respectively, and their frequent clinical
use. Furthermore, their assays are easy to perform, accurate,
reproducible, and without interference from the other sub-
stances in our test solutions [11, 12].
Materials
Drugs
Commercial parenteral phenytoin as phenytoin sodium
(Dilantin®, Parke—Davis, Morris Plains, New Jersey, USA), 250
mg/5 ml ampoules, and gentamicin solutions prepared from
gentamicin sulfate powder were used exclusively. The genta-
micin solutions were prepared immediately prior to each exper-
iment and the powder was stored in the dark. The phenytoin
preparation is in a glycol solvent and mixes poorly in water
solutions, including those used in these studies. There was no
problem in mixing it into plasma or blood.
Filter, lines and pump
Minifilters were used exclusively. These devices are 7.5 cm in
length, 1.3 cm in diameter and contain 25 hollow fiber
polysulfone capillaries. The circuit consisted of the filter, mod-
ified hemodialysis blood lines, a variable speed blood pump, a
reservoir (kept in a warm dynamic state by a magnetic stir-
rer—heater) and pre- and post-filter sampling parts. The arterial
pick—up line exited from the reservoir through the roller pump,
past the arterial sampling port to the filter. The venous line
exited the filter, past the venous sampling port and back to the
reservoir. Fluid replacement was directly into the reservoir.
The ultrafiltrate exited directly from the filter into collection
tubes. The ultrafiltration rate (UFR) was controlled by partial
occlusion of the venous line. New minifilters were used for each
experiment unless otherwise stated.
Solutions
Multiple solvent systems were studied. These solutions were
prepared by the following techniques:
Plasma. Plasma was pooled from patients undergoing plas-
mapheresis for myasthenia gravis.
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Uremic plasma Uremic whole Uremic
water plasma bloodChemical profile
Urea nitrogen ,ngldl 71 1 61 2 35 F
Creatinine mgldl 8.6 0.1 6.9 ° 0.5 3.7 + 0.1
Albumin g/dI 0.1 0.03 2.! 0.3 2.4 0.1
Total protein gidi
inlet 0.1 0.01 3.3 + 0.3 3.4 + 0
outlet 0.1 + 0.01 3.4 + 0.3 3.4 0.1
Total Ca n?g/dl 8.0 0.5 8.5 0.4 9.7 0.1
Na mEqiliter 135 42 —
K mEqiliter 4.1 3.9 ——
Uremic plasma water. The ultrafiltrates were pooled from
patients undergoing isolated ultrafiltration as part of a hemodi-
alysis procedure or from selected patients undergoing CAVH.
Uremic whole plasma. Plasma was ultraflltered through an
Amicon Diafilter 20® (Amicon, Danvers, Massachusetts, USA)
to remove plasma water. This plasma water was replaced with
uremic plasma water.
Blood. Outdated 0-positive red blood cell packs were pro-
cured from the blood bank and were thoroughly and gently
mixed with uremic plasma to a hematocrit of 30%.
Saline. 0.9% saline was obtained from a commercial Lv, fluid
manufacturer.
Donors were not taking any medication known to interfere
with phenytoin or gentamicin assays or protein binding. Just
prior to any experiments, the solutions were passed through a
20 micron high capacity transfusion filler to remove any debris.
The biochemical profiles of these solutions are displayed on
Table 1.
Free fatty acids (FFA). Soy bean oil was hydrolyzed and the
resultant FFAs were extracted.
Methods
Definition of sieving coefficient (S)
Colton and associates derived a rigorous mathematical
expression for the sieving coefficient of a solute [13], which at
any point along the filter is defined as the solute concentration
in the ultrafiltrate divided by the solute concentration in the
plasma water component of the retained fluid. They demon-
strated that the rigorous expression could be abbreviated with-
out introducing a major error to s — 2 UF where UF is theA+V
solute concentration in the ultrafiltrate, A is the solute concen-
tration in the plasma water component at the filter arterial inlet,
and V is the solute concentration in the plasma water compo-
nent at the filter venous outlet.
I)rug assays. Both gentamicin and phenytoin assays were
performed on an Abbott TDX® by fluorescence polarization
immunoassay [11, 12]. Heparin at the concentrations used in
this study do not affect the assays.
The solvent in the reservoir was kept at 34°C. Hcparin at I
unit/mI was added and the pH adjusted to 7.3. A 30 minute
incubation" period allowed the solvent to flow through the
circuit without ultrafiltration occurring. When ultrafiltralion
was induced by a screw clamp on the venous line, the UFR was
kept constant. Therefore, the transmembrane pressure varied
and was not measured. The UFR was similar throughout the
following experiments. The ultrafiltrate dead space was kept to
a minimum.
Effects of solvent, drug concentration, and solvent flow rate
on drug sieving
Gentamicin and phenytoin concentrations were increased in a
stepwise fashion for three concentrations of each (gentamicin 2,
6 and 8 mg/liter; phenytoin 5, 10 and 20 mg/liter) by the addition
of supplemental doses to the reservoir. At each concentration
the solvent flow was progressively increased from 15 to 30 to 45
mI/mm. One filter was used for each solvent, uremic plasma
water, uremic whole plasma, and uremic blood. Samples were
obtained from the arterial inlet (A), venous outlet (V) and
ultrafiltrate port (UF) at five minute intervals for each pump
speed and drug concentration. Data from these experiments
were used to compare values for sieving coefficients defined as
UF/A and 2 UF/(A + V).
Displacement effect of FFAs. Phenytoin sieving was deter-
mined before and after the addition of FFAs to uremic whole
plasma.
Effects of uremia, protein concentration polarization, protein
and membrane interactions, and membrane on phenytoin
sieving
A series of experiments using the same filter were conducted.
The experiment and rationale arc described below and will be
referred to by their number as listed here. In these experiments
the sieving coefficient was defined by UF/A.
Experiment 1: Phenytoin in uremic water—used as control.
Twenty minutes of control filtration occurred, then filtrate
aliquots were collected every five minutes x 3.
Experiment 2: /'henytoin in normal whole plasma. This
experiment reiterates the effect of plasma protein binding on
phenytoin sieving. Fifty minutes of control filtration occurred,
then filtrate aliquots were collected every five minutes x 3.
Experiment 3: Phenyroin in uremic whole plasma. Experi-
ments 2 and 3 compare the effect of uremia on phenytoin sieving
(protein—binding). Also Experiments 2 and 3 expose the mem-
branes to phenytoin and protein. Thirty minutes of control
filtration occurred, and then filtrate aliquots were collected
every 5 minutes x 3.
Experiment 4: Phenytoin in ureinic water. UFR was fixed to
collect ten successive IJF aliquols of 1 ml each. This solvent
was the same as used in Experiment 1. The data from Experi-
ment 4 would be compared to Experiments 1 and 3 to assess the
effect of the previous presence of protein (Exp. 2 and 3) on
phenytoin sieving. Furthermore, the solvent in Experiment 4
may help rinse protein from the membranes.
Experiment 5: 0.9% saline without phenytoin. Samples were
obtained as in Experiment 4, except that urea concentration
was also determined. Urea did not bind to proteins or mem-
branes and served as a marker of dilution from the saline.
Additional complementary experiments to assess protein and
rnenhrane effects.
A new filter was used for Experiments 6 through 10. The
experiments were performed sequentially such that the filter
Table I. Chemical profiles of solvents (mean SD)
Solvents
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membranes were not exposed to circulating proteins until
Experiment 9.
Experiment 6: Phenytoin in 0.9% saline. This was used for
control and to initiate exposing the filter membranes to
phenytoin. Control filtration occurred for 20 minutes followed
by every five minute filtrate collection x 3.
Experiment 7: Phenytoin in uremic plasma water. Urea acted
as a marker of dilution. This experiment used the same collec-
tion periods as in Experiment 6.
Experiment 8: Saline without phenytoin. Aliquots were col-
lected as in Experiment 4 for phenytoin and urea. Since the
membranes had not been exposed to protein, any changes in
phenytoin sieving must be due to membrane—phenytoin inter-
action.
Experiment 9: Phenytoin in uremic whole plasma. Control
filtration occurred for two hours, then phenytoin and urea were
measured at A and UF every ten minutes for an hour, then
every twenty minutes for another hour. Protein concentration
polarization should occur in this setting.
Experiment 10: Phenytoin in 0.9% saline. Samples were
collected for phenytoin and urea as in Experiment 5. This
evaluates the residual effects of the protein on the membranes
(from Experiment 9).
Statistical methods
Data were analyzed by an analysis of variance with multiple
range testing (Student—Newman—Keuls, SPSS), unless other-
wise stated. Reliability of the abbreviated formula for sieving
was assessed by linear regression and correlation coefficient.
Statistical significance was defined as a P < 0.05. Results are
presented as means one SD.
Results
Calculation of the sieving coefficient (5)
In the series of experiments designed to assess drug sieving in
the three different solvents, at three solvent flow rates and at
three different drug concentrations, we compared the Colton—
Henderson abbreviated formula for 5, 2 UF/(A + V), to a
UFfurther abbreviated formula, —. We collected A, V, and UP
A
samples under all conditions studied. We then compared the
sieving coefficients defined as either UF/A or 2UF/(A + V) by
linear regression. The following equations were derived:
2UF UF
for gentamicin = 0.945 x — + 0.045A+V A
where r = 0.979 (P < 0.00001) and
2UF UF
for phenytoin = 0.960 x + 0.007A+V A
where r = 0.997 (P < 0.00001).
Thus, under the conditions of these studies in which the solvent
flow rates are similar to those in CAVH, S can be accurately
defined by , avoiding the necessity of obtaining the venousA UF
sample. Hereafter in this report, S is defined by —.
Table 2. Effect of drug concentration, solvent flow rate and solvent
on drug sieving
Phenytoina Gentamicin5
Cone I Conc 2 Cone 3 Conc 1 Cone 2 Cone 3
Uremic plasma water
flow rate 1 0.88' 0.83 0.67 0.87 0.92 0.92
flow rate 2 1.14 0.79 0.99 0.90 0.95 0.95
flow rate 3 1.53 1.23 1.21 0.95 0.95 1.02
Uremic whole plasma
flow rate 1 0.06 0.08 0.12 0.66 0.91 0.88
flow rate 2 0.08 0.09 0.14 0.81 0.87 0.89
flow rate 3 0.11 0.10 0.13 0.80 0.88 0.89
Uremic blood
flow rate 1 0.10 0.05 0.05 0.91 0.83 0.81
flow rate 2 0.08 0.06 0.05 0.84 0.84 0.77
flow rate 3 0.07 0.06 0.06 0.92 0.87 0.86
a Phenytoin cone 1 5 mg/liter, cone 2 10 mg/liter and cone 3 20
mg/liter
' Gentamicin cone 1 = 2 mg/liter, cone 2 = 5 mg/liter, cone 3 = 8
mg/liter
Flow rate 1 = 15 mI/mm, flow rate 2 = 30 ml/min and flow rate 3 =
45 mI/mm
d Each number represents the mean of three observations
Effect of solvent, solvent flow rate, and drug concentration
on S
UPTable 2 displays the sieving coefficients, —, observed for
three concentrations of phenytoin and gentamicin in three
solvents during variation of the solvent flow rate through the
minifilter. Within the conditions of this study for all three
solvents and all three flow rates, solvent flow rate did not
significantly affect the sieving coefficients of either phenytoin or
gentamicin. Drug concentration affected sieving differently in
plasma and blood. In plasma increasing either drug's concen-
tration increased sieving. Phenytoin S rose progressively from
0.08 0.03 (mean SD) at the lowest concentration to 0.13
0.02 (P < .05) at the highest concentration. Gentamicin S rose
progressively with increasing concentration in plasma from 0.76
0.09 to 0.88 0.03 (P < .05). In blood the opposite was
observed, As drug concentration rose, sieving progressively
declined. Phenytoin S fell from 0.08 0.02 to 0.05 0.01 (P <
0.05) and gentamicin S fell from 0.89 0.06 to 0.82 0.07 (P <
0.05).
In this series of experiments, for all phenytoin observations
in water, S was 1.03 0.27, in plasma 0.10 0.03, and in blood
0.06 0.02 (water vs. plasma, P < 0.001; water vs. blood, P <
0.001, plasma vs. blood, NS). For all gentamicin observations
in water, S was 0.94 0.04, in plasma 0.85 0.07, and in blood
0.85 0.01 (water vs. plasma, P < 0.001; water vs. blood, P <
0.001; plasma vs. blood, NS).
Drug displacement from protein by FFAs
Phenytoin sieving rose from 0.08 0.01 (N = 3) to 0.15
0.03 (N = 3) by the addition of FFAs to phenytoin in uremic
whole plasma (P < 0.05, Mann—Whitney U). The FFA acid
level rose sixfold (to 2500 pEq/liter) and into the abnormal
range after the addition of exogenous FFAs.
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Fig. 1. Saline alone is pumped through a filter which had previously
been exposed to phenytoin in whole plasma and phenytoin in uremic
water. Timed UF aliquots were assayed for urea (•) and phenytoin (0)
and plotted here. Compared to urea, there appears to be a delay in the
phenytoin washout.
Effrct of uremia on phenytoin sieving (Experiments 2 and 3)
Phenytoin sieving in normal whole plasma was 0.09 0.03 (N
= 3). This was not different from the S in uremic whole plasma
of 0.09 0.02 (N 3).
Effrcts of protein and membrane on phenytoin sieving
From Experiment I, the S of phenytoin in uremic plasma
water was 0.86 0.12 (N = 3). From the earlier solvent, flow
and concentration studies (Table 2) it was 1.03 0.27, and from
Experiment 6 it was 1.10 0.17 (N = 3). In Experiments 2 and
3, and from Table 2 data, the S of phenytoin in whole plasma,
normal or uremic, is tightly bunched near 0.10. This difference
between the sieving in water and plasma is consistent with the
known protein binding characteristics of phenytoin 14], but
other effects of the protein (concentration—polarization gel layer
formation, protein—membrane interactions) or membrane—drug
interactions may be contributing to the decreased sieving noted
in plasma. Several series of experiments were designed to
investigate these possibilities.
Run consecutively through the same filter were three soltw
tions: first, phenytoin in urcmic whole plasma (Exp. 3), then
phenytoin in uremic plasma water (Exp. 4), and finally, saline
alone (Exp. 5). The results of Experiment 5 are plotted in Figure
1, where timed aliquots of ultrafiltrate were assayed for
phenytoin and urea, If the observation at aliquot #3 is disre-
garded, there appears to be a delay in the phenytoin washout
when compared to urea. If these observations are interpreted as
showing no delay, the following studies are not necessary.
Assuming a "worst case scenario" we elected to interpret these
observations as demonstrating a delay in phenytoin washout.
This could be due to: 1.) a residual effect of the previous
presence of protein (Exp. 3); 2.) the slow release of membrane—
bound phenytoin accumulated in Experiments 3 and 4; or 3.) a
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Fig. 2. Saline alone is pumped through a filter which had previously
been exposed to phenytoin in uremic water, but not to any protein
containing solvent. Timed UF aliquots were assayed for urea (•) and
phenytoin (0) and plotted here. The phenytoin washout appears more
complete than in Figure 1 (Exp. 5).
combination of the two. To assess this possible phenomenon
further, additional experiments were undertaken.
Run consecutively through a different filter were the follow-
ing solutions: phenytoin in saline (Exp. 6), phenytoin in urcmic
plasma water (Exp. 7, urea acting as a marker), then saline
without phenytoin (Exp. 8). The results of Experiment 8 are
plotted in Figure 2, where timed aliquots of ultrafiltrate were
assayed for urea and phenytoin. As in Figure 1 (Exp. 5) there
appears to be a delay in the washout of phenytoin into the
ultrafiltrate, but unlike Experiment 5, the membrane in Exper-
iment 8 (Fig. 2) had not been previously exposed to plasma
proteins. In Figure 1 the urea curve parallels the phenytoin
curve from aliquot 5 to 10. In Figure 2, possibly because of the
absence of membrane exposure to protein, ultrafiltrate
phenytoin concentrations continue to decline, and the curve
eventually meets the urea curve within the same time frame.
Thus, the membrane may slightly retard phenytoin appearance
in the uitrafiltrate (Fig. 2) and the previous presence of protein
enhances this effect (Fig. 1).
Experiments 3 through 8 evaluated the retention of phenytoin
on the membrane or membrane—protein complex and the ulti-
mate release into the ultrafiltrate. Experiments 9 and 10 were
designed to evaluate whether the membrane—protein complex
permanently interferes with phenytoin sieving in water. In
Experiment 9, phenytoin in uremic whole plasma was run
through a filter for two hours, followed immediately by
phenytoin in saline in the same filter (Exp. 10). The results of
Experiment 10 are plotted on Figure 3. The ultrafiltrate
phenytoin concentration approaches the concentration in the
arterial sleeve (dashed line) after 35 minutes (aliquot 7). The
mean sieving coefficient occurring in aliquots 7 to 10 was 0.94
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Fig. 3. Phenytoin in saline is pumped through afilter previously exposed
to phenytoin in whole plasma. The UF phenytoin concentration ap-
proaches that seen in the arterial sleeve, suggesting the previous protein
exposure has not greatly limited phenytoin sieving in water.
0.01, which is similar to previous observations of phenytoin
sieving in water solutions (Table 2 and Exp. 1). Therefore, the
previous two hour exposure of the membrane to proteins in
Experiment 9 did not significantly affect the later sieving of
phenytoin in the same filter in a water solution.
Discussion
The Colton—Henderson formula for determining the sieving
coefficient of a solute, 2UF__, is the currently acceptedA+V
standard [131. However, we have previously shown for 34 sets
of observations with high sieving drugs than an abbreviated
UF .formula, —, accurately describes drug sieving during CAVH
in humans [51. The present in vitro studies, which simulate the
hemodynamics of CAVH, confirm the in vivo observations for
high sieving drugs and validate the formula for low sieving
drugs like phenytoin. The obvious advantage of our abbreviated
formula is that venous samples are not necessary to make
clinical decisions if sieving is defined as . Furthermore, theA
present studies evaluated drug sieving at varying drug concen-
trations and solvent flow rates, and again , continued to
A
accurately define sieving. Therefore we recommend that for
CAVH, drug sieving be described by
Ronco and associates noted only modest changes in large and
small molecule sieving in CAVH with a blood flow of 60 ml/min,
but at 250 ml/min (by pump) there was a significant reduction in
sieving over time for large molecules only [101. On the other
hand, Frigon and associates did not observe changes in S by
altering solvent flows from 100 to 700 ml/min [9]. Theoretically,
one would not expect changes in S with variation of solvent
flow [6]. Our data confirm that at flow rates of 15 to 45 mllmin,
S is not dependent on solvent flow rate (Table 2).
For the polysulfone membranes used in the present studies
and in similar membranes, the role of molecular size (weight +
steric hindrance) on membrane transport have been extensively
studied [7, 9, 13, 15—18]. Molecules with a molecular weight of
6000 daltons or less will readily traverse these membranes. In a
clinical setting, Dodd and associates noted very high sieving of
Vitamin B12 and inulin in two patients undergoing CAVH with
polysulfone hollow—fiber capillary hemofilters [19].
Therefore, the major limitation to small and middle molecu-
lar—weight solute sieving appears to be the extent of the solute
binding to large, non-ultrafilterable macromolecular proteins in
plasma, especially, but not exclusively, albumin [20, 21]. Drugs
or other solutes bound to these proteins will remain with the
protein during transit through the hemofilter. Only the unbound
fraction has the potential for removal by ultrafiltration. In our
studies we intentionally chose phenytoin because of its high
protein binding and compared its behavior to gentamicin, which
is poorly protein bound. For the highly protein bound
phenytoin, sieving was lowest in blood, low in plasma and high
in water. For the poorly bound gentamicin there was a statisti-
cally significant difference between sieving in water (0.93
0.04) vs. plasma (0.84 0.07) or blood (0.87 0.01), but the
differences are of marginal clinical importance. These data
support the concept that the major limitation to drug sieving is
the extent of drug binding to circulating proteins. The addition
of FFAs to the phenytoin—plasma solution resulted in a dou-
bling of phenytoin sieving, consistent with the fact that FFAs
displace phenytoin from albumin, resulting in a larger unbound
ultrafilterable fraction [22]. FFAs affect the protein binding of
many drugs [231. Drug displacement is clinically important
because the free unbound fraction determines the pharmaco-
logic effect as well as removal by ultrafiltration or hemodialysis
[24]. Heparin can also displace drugs from their protein—binding
sites, but all of our studies were conducted with equal concen-
trations of heparin in the system. We did not note a difference
between phenytoin sieving in uremic whole plasma versus
nonuremic whole plasma in a limited number of observations
(Exp. 2 and 3). However, these studies were clearly not
designed to evalute the displacement effects of uremia because
the pooled plasma only came from a few donors and interpatient
variations were not addressed. These studies were designed to
compare urea and phenytoin appearance in the UF. Phenytoin
protein binding is reduced two—to threefold in humans with
uremia [14]. From our earlier observations phenytoin sieving in
uremic patients is 0.45 [51, which is greater than expected with
normal protein binding. Again, this is consistent with the
concept that drug sieving is predominantly dependent on
protein—binding and displacement of drug from plasma proteins
enhances sieving.
Although increasing the concentration of phenytoin and
gentamicin in whole plasma statistically increased the sieving
coefficients, the amount of free drug lost is not likely to be of
clinical importance. The increased sieving is probably due to
the saturation of protein binding sites by the excess of drug in
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the experiments using larger drug concentrations [21, 251. The
result is a larger percentage of drug unbound and ultrafilterable.
This occurred to a larger extent for phenytoin which is highly
bound, compared to a smaller fractional increase for the poorly
bound gentamicin.
However, raising the drug concentration in whole blood led
to a slight but statistically significant decline in the S of both
drugs. An explanation for the observed decreased sieving in
blood at higher drug concentrations may involve the well
documented compartmentalization of the drugs in red blood
cells. For both gentamicin and phenytoin, 10 to 30% of the
concentration in whole blood is associated with (in or on) red
blood cells [26—281. During the processing of whole blood
samples, the release of red cell—bound drug into the supernatant
may falsely elevate the blood level. Although this level is
measured in separated whole blood, the unbound level present
within the filter during hemofiltration is lower. Thus by defining
S as UF/A or 2UF/(A + V), the denominator is falsely high,
lowering S. Even if the concentration of drug in whole blood
rises, the fractional decline in sieving that we observed is not
likely to be of clinical significance.
The presence of protein in the solvent also decreases the
transmembrane movement of nonprotein—bound test molecules
[9, 13, 15, 18, 29—32]. As transmemhrane pressure rises during
hemofiltration of protein containing solvents, nonultrafiltered
proteins begin to collect along the membrane (concentration
polarization). These proteins form a gel layer which gradually
restricts transmembrane flux by increasing the osmotic pressure
at the membrane and/or by offering an additional solute hydro-
dynamic resistence barrier to flow. Transmembrane flux gener-
ally rises with increased transmembrane pressure. As the
protein layer forms, the transmembrane flux no longer increases
with transmembrane pressures. This phenomenon is readily
observed at the transmembrane pressures generated during
high—flux intermittent hemofiltration. There are no data on this
subject in the setting of CAVH, where transmemhrane pres-
sures and ultrafiltration rates are considerably less, Although
we did not specifically measure transmembrane pressure, we
fixed it at a high level to evaluate the effect of protein concen-
tration polarization on phenytoin sieving (Exp. 1—10). We found
that although the effects of the protein layer and protein
membrane interactions are present under the conditions of our
study, these effects are quantitatively small and do not exist
when protein—free solvents are used.
Figure 1 plots the disappearance of urea and phenytoin in
timed ultrafiltrate aliquots when pure saline alone was pumped
through the filter. Phenytoin in whole plasma previously circu-
lated in this filter. The difference in the shape of the urea and
phenytoin curves may be due to a residual effect of the previous
protein and/or the slow release of membrane—bound phenytoin.
Figure 2 plots the results of a similar experiment except that
protein-containing solvents were not employed at any time.
This time the urea and phenytoin curves eventually met,
demonstrating the real, albeit small, effect that protein has on
sieving independent of drug—protein binding. Lastly, Figure 3
demonstrates that this effect of protein can be reversed. Every
five minutes, UF aliquots were measured for phenytoin when
the solvent was phenytoin in saline. Previously this filter had
been exposed to a protein containing solvent. If the protein
effect had persisted the UF phenytoin concentrations would not
have risen as high as they did. Although the UF levels did not
equal the arterial levels, from aliquot 7 on, the S is what one
would expect in saline solutions. From the experiments plotted
in Figures 1 to 3, we observed that the membrane and the
membrane—protein complex have a small effect on phenytoin
sieving. The clinical relevance of these effects is not clear from
these studies, but it seems unlikely that protein concentration
polarization is playing much of a role in drug sieving in CAVH.
In summary, from the present studies designed to simulate
CAVH in vitro, we conclude that the sieving coefficient for
drugs can be represented as. This holds true for high and
low sieving drugs. Drug sieving is independent of solvent flow
rate. When drug concentrations in plasma are increased, sieving
increases, which we speculate is due to saturation of protein
binding sites. In whole blood as drug concentration rises there
is a slight decrease in drug sieving, thought to he an in vitro
effect during the assay related to drug compartmentalization
into red cells. In any case the changes in S with changes in drug
concentration are small enough to be ignored clinically. Lastly,
protein and protein—membrane interactions with drugs are real,
hut small, and probably not clinically important. Our observa-
tions are consistent with the expectation that the major deter-
minant of small to middle molecule solute sieving is the extent
of solute—protein binding. Drug displacement from protein
binding sites will increase sieving and ultrafiltrate losses.
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